Publications by authors named "Roger Maansson"

Claim this Profile
A
A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix Vaccine When Given to Healthy Infants at 3 and 12 Months of Age.
Susanna Koski, Federico Martinon-Torres, Mika Rämet, Lefteris Zolotas, Ryan Newton, Roger Maansson

Infect Dis Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose.
James Peterson, Daniel Drazan, Beth Moughan, Jason D Maguire, Lefteris Zolotas, Roger Maansson

Vaccine· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
James Peterson, Daniel Drazan, Hanna Czajka, Jason Maguire, Jean-Louis Pregaldien, Roger Maansson

Lancet Infect Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.
Helen S Marshall, Timo Vesikari, Peter C Richmond, Jacek Wysocki, Leszek Szenborn, Roger Maansson

Lancet Infect Dis· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.
Johannes Beeslaar, Susan Mather, Judith Absalon, Joseph J Eiden, Laura J York, Roger Maansson

Vaccine· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
Daniel Drazan, Hanna Czajka, Jason D Maguire, Jean-Louis Pregaldien, Roger Maansson

Vaccine· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
Lars Østergaard, Timo Vesikari, Shelly D Senders, Carl-Erik Flodmark, Pavel Kosina, Roger Maansson

Vaccine· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data.
Johannes Beeslaar, Paula Peyrani, Judith Absalon, Jason Maguire, Joseph Eiden, Roger Maansson

Infect Dis Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies.
Johannes Beeslaar, Judith Absalon, Annaliesa S Anderson, Joseph J Eiden, Paul Balmer, Roger Maansson

Infect Dis Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
Timo Vesikari, Lars Østergaard, Johannes Beeslaar, Judith Absalon, Joseph J Eiden, Roger Maansson

Vaccine· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling excess zeroes in an integrated analysis of vaccine safety.
Roger Maansson, David Radley, Qin Jiang, Johannes Beeslaar, Scott Patterson

Hum Vaccin Immunother· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.
Johannes Beeslaar, Judith Absalon, Paul Balmer, Amit Srivastava, Roger Maansson

Vaccine· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
Lars Ostergaard, Timo Vesikari, Judith Absalon, Johannes Beeslaar, Brian J Ward, Roger Maansson

N Engl J Med· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials.
Lone K Petersen, Jaime Restrepo, Edson D Moreira, Ole-Erik Iversen, Punnee Pitisuttithum, Roger Maansson

Papillomavirus Res· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
Alain Luxembourg, Darron Brown, Celine Bouchard, Anna R Giuliano, Ole-Erik Iversen, Roger Maansson

Hum Vaccin Immunother· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine.
Alain Luxembourg, Edson D Moreira, Rudiwilai Samakoses, Kyung-Hyo Kim, Xiao Sun, Roger Maansson

Hum Vaccin Immunother· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines.
Andrea Schilling, Mercedes Macias Parra, Maricruz Gutierrez, Jaime Restrepo, Santiago Ucros, Roger Maansson

Pediatrics· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and Safety of a 9-Valent HPV Vaccine.
Pierre Van Damme, Sven Eric Olsson, Stanley Block, Xavier Castellsague, Glenda E Gray, Roger Maansson

Pediatrics· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age.
Pope Kosalaraksa, Jesper Mehlsen, Timo Vesikari, Aino Forstén, Klaus Helm, Roger Maansson

Pediatr Infect Dis J· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

BMJ· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
Susanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, Mauricio Hernandez-Avila, Cosette M Wheeler, Roger Maansson

Cancer Prev Res (Phila)· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.
Sven-Eric Olsson, Susanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, Mauricio Hernandez-Avila, Roger Maansson

Hum Vaccin· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis